University of Ottawa, Ottawa, ON, Canada.
Osteoporos Int. 2012 Feb;23(2):751-60. doi: 10.1007/s00198-011-1621-2. Epub 2011 Apr 15.
Eighty children with nephrotic syndrome underwent lumbar spine densitometry and vertebral morphometry soon after glucocorticoid initiation. We found an inverse relationship between glucocorticoid exposure and spine areal bone mineral density (BMD) Z-score and a low rate of vertebral deformities (8%).
Vertebral fractures are an under-recognized complication of childhood glucocorticoid-treated illnesses. Our goal was to study the relationships among glucocorticoid exposure, lumbar spine areal BMD (LS BMD), and vertebral shape in glucocorticoid-treated children with new-onset nephrotic syndrome.
Lateral thoracolumbar spine radiography and LS BMD were performed in 80 children with nephrotic syndrome (median age 4.4 years; 46 boys) within the first 37 days of glucocorticoid therapy. Genant semiquantitative grading was used as the primary method for vertebral morphometry; the algorithm-based qualitative (ABQ) method was used for secondary vertebral deformity analysis.
Six of the 78 children with usable radiographs (8%; 95% confidence interval 4 to 16%) manifested a single Genant grade 1 deformity each. All deformities were mild anterior wedging (two at each of T6, T7, and T8). Four of the 78 children (5%; 95% confidence interval 2 to 13%) showed one ABQ sign of fracture each (loss of endplate parallelism; two children at T6 and two at T8). Two of the children with ABQ signs also had a Genant grade 1 deformity in the same vertebral body. None of the children with a Genant or ABQ deformity reported back pain. An inverse relationship was identified between LS BMD Z-score and glucocorticoid exposure.
Although we identified an inverse relationship between steroid exposure and LS BMD soon after glucocorticoid initiation for childhood nephrotic syndrome, there was only a low rate of vertebral deformities. The clinical significance of these findings requires further study.
八十名肾病综合征患儿在开始使用糖皮质激素后不久接受了腰椎骨密度和椎体形态测量。我们发现糖皮质激素暴露与脊柱面积骨密度(BMD)Z 评分呈负相关,且椎体畸形发生率较低(8%)。
椎体骨折是儿童糖皮质激素治疗疾病中一种未被充分认识的并发症。我们的目标是研究新诊断肾病综合征患儿糖皮质激素治疗期间糖皮质激素暴露、腰椎面积 BMD(LS BMD)和椎体形态之间的关系。
80 名肾病综合征患儿(中位年龄 4.4 岁;46 名男性)在糖皮质激素治疗的第 37 天内接受了侧位胸腰椎脊柱放射摄影和 LS BMD 检查。Genant 半定量分级被用作椎体形态学的主要方法;基于算法的定性(ABQ)方法被用于次要的椎体畸形分析。
78 名有可评估放射照片的患儿中有 6 名(8%;95%置信区间 4 至 16%)各出现 1 处 Genant 1 级畸形。所有畸形均为轻度前楔形(T6、T7 和 T8 各 2 处)。78 名患儿中有 4 名(5%;95%置信区间 2 至 13%)各出现 1 处 ABQ 骨折征象(终板平行性丧失;6 处和 8 处各 2 处)。2 名出现 ABQ 征象的患儿同一椎体也有 Genant 1 级畸形。没有出现 Genant 或 ABQ 畸形的患儿报告有背痛。LS BMD Z 评分与糖皮质激素暴露呈负相关。
尽管我们在开始糖皮质激素治疗儿童肾病综合征后不久发现了皮质类固醇暴露与 LS BMD 之间的负相关,但椎体畸形的发生率仍然较低。这些发现的临床意义需要进一步研究。